The FDA approved Eli Lilly and Company’s Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1… read more.
Results from the real-world ZORA observational multi-country study presented at the American Society of Nephrology (ASN) 2023 shows that treating hyperkalaemia (HK) with the potassium binder Lokelma (sodium… read more.
Gedeon Richter Plc. together with Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH has announce that the European Commission (‘EC’) has granted approval of a Type II… read more.
Mirati Therapeutics, Inc. a commercial stage biotechnology company, announced the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for Krazati (adagrasib) as… read more.
Amgen announced new data for Krystexxa (pegloticase) showing a decrease in blood pressure during treatment of adults living with chronic gout refractory to oral urate-lowering treatment; uncontrolled gout,… read more.
Otsuka Pharmaceutical has filed its antipsychotic agent Rexulti (brexpiprazole) in Japan for a label expansion into agitation associated with dementia due to Alzheimer’s disease. If approved, it would… read more.
For the first time, a panel of spinal cord stimulation (SCS) experts has developed best practices in the nascent field of remote SCS device management . The recommendations… read more.
SeaStar Medical Holding Corporation announces receipt of a correspondence from the FDA Center for Biologics Evaluation and Research (CBER) indicating that the Agency considers the Selective Cytopheretic Device… read more.
LianBio a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced topline results from the Phase III LIBRA clinical trial… read more.
Galapagos NV and Alfasigma S.p.A. announced that they have signed a letter of intent contemplating a transfer of the Jyseleca business to Alfasigma, including the European and UK… read more.
Eli Lilly and Company announced that the FDA has approved Omvoh (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment… read more.
Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (TEER) therapies, as well as… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
